Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Von Willebrand Diseases

In brief

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

Key facts

Study ID
NCT05776069
Run by
Vega Therapeutics, Inc
People needed
116
Starts
2023-03-16
Expected to finish
2029-12-01
Last updated by the study team
2025-08-26

Who can join

Age: 12 and older, up to 60. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.